Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer Journal Article

Authors: Motzer, R. J.; Sheinfeld, J.; Mazumdar, M.; Bains, M.; Mariani, T.; Bacik, J.; Bajorin, D.; Bosl, G. J.
Article Title: Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer
Abstract: Purpose: To evaluate the dose, toxicity, and efficacy of paclitaxel in combination with ifosfamide and cisplatin as salvage therapy for patients with relapsed testicular germ cell tumors (GCTs). Patients and Methods: Thirty patients with previously treated GCTs were treated with paclitaxel and ifosfamide plus cisplatin (TIP) as second-line therapy. All had favorable prognostic features for response (testis primary tumor site and prior complete response to first-line chemotherapy program). Four cycles of paclitaxel, ifosfamide 5 g/m2, and cisplatin 100 mg/m2 were given 21 days apart with granulocyte colony-stimulating factor support, followed by resection of radiographic residua. The dose of paclitaxel was increased among cohorts with dose levels of 175, 215, and 250 mg/m2; the largest dose was selected for the phase II part of the trial. Results: Twenty-three (77%) of 30 patients achieved a complete response to chemotherapy alone, and one patient achieved a durable partial response with normal tumor markers. Therefore, 24 (80%) achieved a favorable response. Eleven patients with normalized markers after chemotherapy underwent resection of residual tissue, with only necrosis found in 10 and mature teratoma in one. Two patients relapsed, and 22 (73%) of the favorable responses remain durable at a median follow-up duration of 33 months. Myelosuppression was the major toxicity, and two patients had grade 3 neurotoxicity. Conclusion: Four cycles of TIP was associated with a high proportion of patients who achieved a complete response, a lack of relapse, and relative tolerability as an ifosfamide- containing salvage regimen for testicular GCTs. The high durable complete response proportion emphasizes the importance of patient selection according to prognostic factors for a favorable outcome to conventional-dose salvage therapy. (C) 2000 by American Society of Clinical Ontology.
Keywords: adult; clinical article; treatment outcome; middle aged; cancer recurrence; salvage therapy; cisplatin; cancer combination chemotherapy; paclitaxel; neoplasm recurrence, local; bone marrow suppression; antineoplastic combined chemotherapy protocols; drug administration schedule; antineoplastic activity; ifosfamide; testicular neoplasms; taxoids; germ cell tumor; granulocyte colony stimulating factor; granulocyte colony-stimulating factor; germinoma; humans; human; male; priority journal; article
Journal Title: Journal of Clinical Oncology
Volume: 18
Issue: 12
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2000-06-12
Start Page: 2413
End Page: 2418
Language: English
PUBMED: 10856101
PROVIDER: scopus
Notes: Export Date: 18 November 2015 -- Source: Scopus
Citation Impact
MSK Authors
  1. Dean Bajorin
    597 Bajorin
  2. Robert Motzer
    1072 Motzer
  3. Madhu Mazumdar
    127 Mazumdar
  4. Joel Sheinfeld
    241 Sheinfeld
  5. Manjit S Bains
    300 Bains
  6. George Bosl
    417 Bosl
  7. Jennifer M Bacik
    46 Bacik